Award winning S. Epatha Merkerson, Television, film and stage actress, brings a new order to her diabetes management: Get to Your Goals Program, which encourages people with type 2 diabetes to know their A1C, set a goal and take action. 11 years ago Merkerson was at celebrity health event where good nutrition and exercise was … Continue reading Actress S. Epatha Merkerson Brings Order to Her Diabetes
The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and … Continue reading FDA Backtracks Over GLP-1s’ Effects on Pancreas
Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies. According to Lilly, dulaglutide, a GLP-1 analog, worked better to … Continue reading Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs
The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC. Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of … Continue reading FDA OKs Sale of Combo Drug JANUMET
If you have diabetes, you know all too well what’s going to happen between now and the end of the year. You’ll be forced to make some quick and painful decisions at sumptuous holiday feasts. Do you refuse the lavish, carbohydrate-rich fare and give up on the fun of the season? Or do you go … Continue reading Are You Prepared for the Holidays?
Drug company Merck aims to give people with type 2 diabetes two treatments for the price of one. The new therapy, called Juvisync, was just approved by the US Food and Drug Administration. It’s not a radical new treatment, but instead a helpful combination of two familiar standbys: Juvisync unites the active ingredients in blood … Continue reading New Type 2 Drug Targets Blood Sugar and Cholesterol